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Abstract
Mammary neoplasms are described as the third most common type of feline tumor, after haematopoietic and skin 
tumors, and present a challenge for clinicians because the prognosis for feline mammary tumors ranges from guarded 
to poor. Thus, it is necessary to define new therapeutic approaches and establish more in-depth knowledge about 
this disease in felines. The main aspects of the diagnosis, prognosis and treatment of feline mammary neoplasia were 
discussed, aiming to standardize the criteria and to serve as a guide for pathologists and veterinary clinicians.
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Resumo
As neoplasias mamárias são descritas como o terceiro tipo mais frequente de tumor em felinos (após as neoplasias 
hematopoiéticas e cutâneas) e apresentam um desafio para os clínicos devido ao prognóstico, que varia de reservado a 
ruim. Assim, é necessário conhecer melhor essa doença em felinos e definir novas abordagens terapêuticas. Discutiu-
se os principais aspectos de diagnóstico, prognóstico e tratamento da neoplasia mamária felina, com o objetivo de 
padronizar os critérios e servir de guia para patologistas e clínicos veterinários. 
Palavras-chave: Neoplasia. Felinos. Patologia. Terapêutica.
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Introduction
During the 1st and 2nd Mammary Pathology Meeting in 
2011 and 2013, which resulted in the Cassali et al. (2011) 
and Cassali et al. (2014) publications, respectively, 
several participants requested that the main aspects of 
feline mammary neoplasms should also be addressed. 
Due to some particularities of these tumors in the cat, 
a specific discussion was required. Thus, at the 3rd 
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Mammary Pathology Meeting, held on October 20-21, 
2016 in Salvador, Brazil, the main aspects of the diagnosis, 
prognosis and treatment of feline mammary neoplasms 
were discussed, aiming to standardize the criteria and serve 
as a guide for pathologists and veterinary clinicians.
Epidemiology and risk factors
Mammary neoplasms are described as the third most 
common type of feline tumor, after haematopoietic and 
skin tumours (MACEWEN et al., 1984; MISDORP, 2002; 
OVERLEY et al., 2005; LANA et al., 2007). However, 
in a survey conducted in Brazil, mammary neoplasms 
represented the second most common type of tumor in 
the species (Togni et al., 2013). Its highest incidence is 
observed between 10 and 11 years of age (MISDORP, 2002) 
and in intact females (LANA et al., 2007). Intact cats have 
a seven-fold higher risk of developing mammary tumors 
when compared to spayed cats (WALDROW, 2001; 
OVERLEY et al., 2005; SORENMO, 2013).
In Brazil, a breed predisposition was not observed 
(CUNHA et al., 2016), as opposed to a previous 
international study that found Siamese cats to be more 
predisposed to mammary tumors (SORENMO et al., 2013). 
This fact is likely due to the domestic feline population in 
Brazil being predominantly composed of mongrel cats 
(CUNHA et al., 2016).
As has been observed in women and bitches, 
hormones also have a strong influence on mammary 
tumor development in cats. Early spaying, from six 
to 12  months, reduces the risk of mammary tumor 
formation in cats (RUTTEMAN et al., 2001; OVERLEY 
et al., 2005). The risk of mammary tumor development in 
cats spayed before six months of age is reduced by 91%; in 
those spayed before one year of age, the risk is reduced up 
to 86%; and, in contrast, the risk is only reduced by 11% 
when the animals are spayed between 13 and 24 months 
of age (OVERLEY et al., 2005; LANA et  al.,  2007).
Clinical and pathological aspects
At least 80% of feline mammary tumors are malignant 
(BOSTOCK, 1986; MISDORP et al., 1999). Many of 
these, especially large and invasive tumors, adhere to 
the skin and are ulcerated. In addition, lymph vessel and 
lymph node invasion are common. Regional and distant 
metastases can be observed in more than 80% of cats 
with malignant mammary tumors (LANA et al., 2007) 
and most often affect the lungs, although they can also 
be found in the pleura, liver, diaphragm, adrenal glands, 
spleen, kidneys, uterus and ovaries (WEIJER, 1972; 
HAYES, 1981; SORENMO, 2013). Multiple mammary 
gland involvement is frequent and can be observed and, 
just as in bitches, the abdominal mammary glands are 
the most affected (BORREGO, 2009; SORENMO, 2013; 
CAMPOS  et al.,  2014). The prognosis is guarded to 
poor, and the average survival time is less than one year 
(OVERLEY et al., 2005; LANA et al., 2007).
Clinical staging
Clinical staging in female mammary tumors has the 
objective of evaluating the size of the primary tumor, 
the involvement of the regional lymph nodes (axillary 
and inguinal) and the presence of distant metastasis, 
which allows establishing a prognosis and planning 
the treatment. Clinical staging should be performed 
according to the staging system of the World Health 
Organization (OWEN,  1980), modified for feline 
mammary tumors (Table 1; BORREGO et al., 2009; 
MCNEILL et al., 2009).
Table 1 –  Clinical staging of the World Health Organization, 
modified for feline mammary tumors, according to 
the TNM system
Stage T N M
I T1 N0 M0
II T2 N0 M0
III
 T1-2
T3
N1
 N0-1
M0
M0
IV   T1,2,3  N0-1 M1
T: size of primary tumor; N: lymph node; M: metastasis; T1: tumor size < 2cm; 
T2: tumor size 2 - 3cm; T3: tumor size > 5cm; N0: no regional lymph node 
metastasis; N1: ipsilateral lymph node involved
Source: Borrego et al. (2009); McNeill et al. (2009)
Histological classification of tumors
Approximately 80% of feline mammary tumors are 
malignant; however, benign lesions also occur. Hyperplasias 
and dysplasias, such as fibroepithelial hyperplasia, lobular 
hyperplasia and duct ectasia, are examples of benign non-
neoplastic lesions (MISDORP, 1999).
Most of the malignant feline mammary tumors are 
classified as adenocarcinomas and are subdivided into 
histological types: tubulopapillary, solid, cribriform and in situ 
carcinoma. Other subtypes found include lipid-rich carcinoma 
(KAMSTOCK et al., 2005), squamous cell carcinoma, 
mucinous carcinoma, carcinosarcoma, adenosquamous 
carcinoma (GIMENEZ et al., 2010), micropapillary 
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carcinoma, papillary carcinoma, tubular carcinoma, 
glycogen-rich carcinoma, malignant adenomyoepithelioma 
and carcinoma in mixed tumour (CAMPOS et al., 2014). 
Inflammatory carcinoma and lymphangiosarcoma have also 
been described (PEREZ-ALENZA, 2004; SUGIYAMA, 2007). 
Table 2 outlines the histological classification of mammary 
tumors in cats.
gland without invasion or discontinuity of the basal 
membrane (Figure 1A). The neoplastic cells can be arranged 
in papillary patterns: micropapillary (Figure 1B), cribriform, 
solid or solid with comedonecrosis (central necrosis).
Tubulopapillary carcinoma: epithelial neoplasia 
characterized by tubular formations and/or papillary 
projections. This lesion type can be divided into tubular 
carcinoma and papillary carcinoma, depending on the 
arrangement found. It is important to differentiate them 
from the cribriform type, which is frequently diagnosed 
in this species (Figure 1C).
Cribriform carcinoma: malignant epithelial neoplasia 
characterized by the formation of secondary lumina, 
forming regular spaces with defined borders (“sieve-like” 
openings). Foci of central necrosis are frequently observed 
(Figure 1D). The coexistence of carcinomatous areas in 
situ with the same pattern is common, with variable 
mitotic indexes.
Solid carcinoma: microscopically, the epithelial cells 
have a solid arrangement, forming leaflets, cords or nests 
of cells with small or moderate amounts of surrounding 
stroma. The cells have a rounded shape, a high nucleus: 
cytoplasm ratio and clearly visible nucleoli. Some solid 
carcinomas may present cells with vacuolated cytoplasm, 
suggesting a possible myoepithelial origin (Figure 2A). 
Areas of necrosis and high mitotic indexes are common.
Micropapillary carcinoma: malignant proliferation 
characterized by epithelial cells arranged in a moruliform 
pattern within cystic spaces. In situ and invasive 
areas can be observed in the same tumor (Figure 2B). 
Usually associated with other histological types, such 
as tubulopapillary carcinomas. Lymphatic invasion and 
lymph node metastasis are often observed.
Carcinosarcoma: malignant tumors composed by 
a population of heterogeneous cells of epithelial and 
mesenchymal origin. Epithelial cells are arranged in solid 
nests, tubules and/or papillae and exhibit prominent ovoid 
nuclei and nucleoli. The mesenchymal proliferation is 
highly cellular, presenting pleomorphic cells in fusiform 
form and elongate to oval nuclei, with moderate to marked 
mitotic indexes. Areas with myxoid, chondroid and/or 
osteoid matrix formation may be observed, along with 
mature adipose and cartilaginous and/or bone tissue, 
possibly containing bone marrow. For poorly differentiated 
tumors, the use of an immunohistochemical technique 
with cytokeratin (CK) and vimentin is suggested 
(PANIAGO et al., 2010; CASSALI et al., 2014).
Table 2 –  Histological classification of feline mammary tumors
Histological classification of feline mammary tumors
1. Malignant tumors
1.1 Non-infiltrating (in situ) carcinoma 
1.2 Tubulopapillary carcinoma 
1.3 Solid carcinowma 
1.4 Cribriform carcinoma 
1.5 Squamous cell carcinoma 
1.6 Mucinous carcinoma 
1.7 Carcinosarcoma
1.8 Carcinoma or Sarcoma in benign tumor
1.9 Micropapillary carcinoma 
1.10 Lipid-rich carcinoma 
2. Benign tumors
2.1 Adenoma 
2.2 Fibroadenoma
2.3 Benign mixed tumor
2.4 Duct papilloma
3. Special types of malignant neoplasms 
3.1 Tubular carcinoma 
3.2 Papillary carcinoma
3.3 Glycogen-rich carcinoma
3.4 Carcinoma in mixed tumor
3.5 Malignant adenomyoepithelioma
4. Non-neoplastic benign lesions 
4.1 Ductal hyperplasia 
4.2 Lobular hyperplasia 
4.3  Fibroadenomatous change (feline mammary hypertrophy, 
fibroepithelial hypertrophy), fibroepithelial hyperplasia 
4.4 Adenosis
4.5 Duct ectasia 
Source: Misdorp et al. (1999); Campos et al. (2015)
Microscopic description of mammary lesions
Malignant tumors
Carcinoma in situ: characterized by neoplastic epithelial 
cells that proliferate both into the lumen of the extralobular 
ducts and to the terminal duct-lobular units of the mammary 
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Figure 1 –  (A) and (B): Carcinoma in situ. Neoplastic epithelial cells that proliferate into the 
lumen without invasion or discontinuity of the basal membrane (arrow); (A): 
Comedocarcinoma with central area of necrosis (N). H&E. 40x; (B): Micropapillary. 
Papillary projections without connective axis. H&E. 40x; (C): Tubulopapillary 
carcinoma. Tubular formations and papillary projections H&E. 10x; (D): Cribriform 
carcinoma. Formation of secondary lumina, forming regular spaces with defined 
borders associated with foci of central necrosis (N). H&E. 10x
Figure 2 – (A); Solid carcinoma. Epithelial cells with a solid arrangement, forming nests of cells with 
small amount of surrounding stroma. H&E. 40x; (B): Micropapillary carcinoma. Epithelial 
cells arranged in a moruliform (arrow) pattern within cystic spaces. H&E. 20x; (C): 
Papillary carcinoma. Pedunculated arborescent branching composed of cubic to columnar 
cells overlying a delicate fibrovascular stromal axis. H&E. 10x; (D). Tubular carcinoma. 
Small invasive tubular structures (arrow) associated with desmoplatic reaction. H&E. 20x
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Malignant adenomyoepithelioma: tumor 
characterized by proliferation of myoepithelial cells that 
exhibit moderate pleomorphism, associated with in situ 
and invasive areas of malignant epithelial cells. Epithelial 
cells exhibit moderate pleomorphism and multiple and 
prominent nucleoli. In general, the cells of this tumor type 
have a low mitotic index.
Papillary carcinoma: papillary carcinomas in the 
cat are generally pure and characterized by sessile or 
pedunculated arborescent branching composed of cubic 
to columnar cells overlying a delicate fibrovascular 
stromal axis (Figure 2C). The frequencies of stromal 
invasion and lymphatic embolization are high, but 
the tumors may be intraductal. Eventually, these 
tumors become cystic and have been called papillary 
cystadenocarcinoma (HAMPE; MISDORP, 1974). 
In women, establishing the diagnosis of intraductal 
papillary carcinoma (ICC) requires that at least 90% 
of the papillae be devoid of myoepithelial cells, which 
can be verified with immunohistochemical evaluation 
and allows a safe distinction between ICC and ductal 
papillomas (TAVASSOLI; DEVILEE, 2004).
Tubular carcinoma: the typical characteristics of 
a pure tubular carcinoma, in which at least 90% of the 
tumor exhibits this histological pattern, are the presence 
of small tubular structures, oval to round, often angulated, 
covered by a single layer of small and regular cells with 
low nuclear pleomorphism and few mitotic figures, with 
incomplete or absent basal membrane and empty lumen 
(Figure 2D). This tumor is essentially invasive, with areas 
of necrosis and a moderate desmoplastic reaction being 
common. The concomitant occurrence with cribriform 
or micropapillary in situ foci is common in women 
(TAVASSOLI; DEVILEE, 2004).
Glycogen-rich carcinoma: microscopic evaluation 
demonstrates epithelial cells arranged in a predominantly 
solid pattern, tumor cells present an ample, granular, and 
foamy clear cytoplasm, and moderate cellular pleomorfism 
(Figure 3A). The presence of cytoplasmatic glycogen 
should be confirmed through diastase digestion followed 
by PAS staining.
Mucinous carcinoma: a rare tumor in cats characterized 
primarily by the abundant presence of intra- or extracellular 
mucin, in association with the proliferation of epithelial 
cells in solid, tubular or papillary arrays arranged in large 
compartments delimited by delicate fibrous septa. They 
can be pure, that is, 100% mucinous, or, more commonly, 
mixed, when other carcinomatous patterns are present. 
Mucin may form small or broad extracellular lakes, 
where it is amphiphilic to slightly basophilic, or may be 
found within the cell cytoplasm, where it stains slightly 
eosinophilic and results in signet ring cells. In most cases, 
the tumor is positive for Alcian blue at pH 2.5, and less 
frequently, it is reactive to periodic acid-Schiff (PAS) with 
diastase, proving to be rich in acid mucopolysaccharides 
(SARLI et al., 2006).
Lipid-rich carcinoma: a rare tumor, one that has 
already been reported in cats, characterized by an 
expansive growth of tubulo-acinar structures delimited 
by dense fibrous septa, which were composed of cohesive 
clusters of round to polygonal cells. These cells had 
eosinophilic, foamy, moderate to wide cytoplasm with 
vacuoles of varying size, round and distinct, repelling the 
nucleus peripherally. The contents of these vacuoles are 
negative for PAS and Alcian blue and positive for oil-red 
(KAMSTOCK et al., 2005).
Benign tumors
Adenoma: benign tumor composed of acinar structures 
presenting a layer of epithelial and myoepithelial cells, 
surrounded by basal membrane. The cells are well 
differentiated and exhibit expansive and porous growth, 
with well-defined borders. Adenoma must be differentiated 
from adenosis because it exhibits loss of the architecture 
with absence of intralobular ducts. Some adenomas may 
exhibit intratubular secretion.
Fibroadenoma: relatively common benign neoplasia in 
cats. It is characterized by a proliferation of epithelial cells 
in a tubular array (see adenoma) enveloped abundantly by 
fibroblast stromal elements. Two subtypes are described: 
pericanalicular, when the epithelial cells are surrounded 
by the stroma, and the intracanalicular, when the epithelial 
cells are compressed and deformed by the stroma 
(Figure 3B). Mitoses are rare.
Benign mixed tumor: proliferation of benign 
epithelial cells in a single layer tubular and/or 
papillary arrangement associated with proliferation 
of myoepithelial cells with benign myxoid and/or 
chondroid matrix and/or bone matrix formation, 
along with mature cartilage and/or bone tissue. The 
architecture can sometimes be quite heterogeneous, and 
the cellular pleomorphism can be moderate, eventually 
leading to a malignant diagnosis by less-experienced 
pathologists.
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Non-neoplastic benign lesions
Ductal hyperplasia: characterized by the proliferation 
of well-differentiated epithelial cells, morphologically like 
the normal cells of the mammary ducts. The cells proliferate 
within the duct and are arranged in one or more layers, 
sometimes forming irregular intraductal bridges. A layer 
of myoepithelial cells is present delimiting the ducts. The 
lesion may be typical or atypical. Typical lesions present 
narrow bridges with elongated and twisted cells that create 
irregular peripheral fenestrations; cells and their nuclei 
differ in appearance and location. Atypical lesions produce 
regularly distributed monomorphic cells with round to 
ovoid nuclei and create more elaborate architectural patterns 
with more robust epithelial bridges. The distinction between 
atypical lesions and low-grade ductal carcinoma in situ may 
be difficult. When cytological and architectural features are 
present throughout the entirety of at least two units, the 
diagnosis of ductal carcinoma in situ is more appropriate.
Lobular hyperplasia: occurs in the terminal portions 
of the lobular units of the mammary glands, which are 
occupied by a uniform overgrowth of cells with low 
pleomorphism and uniform nuclei.
Fibroepithelial hyperplasia: non-neoplastic mammary 
proliferation induced by endogenous or synthetic 
progesterone. Microscopically, it is characterized by 
proliferation of ducts lined by one or more layers of 
epithelial cells, exhibiting low pleomorphism, surrounded 
by edematous and loose connective tissue. Mitotic figures 
are rare, but they can be visualized in both the stroma and 
the epithelium (Figure 3C). The presence of inflammatory 
infiltrate is infrequent. Fibroepithelial hyperplasia 
frequently affects all mammary glands, which are swollen, 
with areas of necrosis and secondary bacterial infection 
(HAYDEN et al., 1981).
Adenosis: characterized by the increased number of 
acini with or without dilation of the intralobular mammary 
ducts, maintaining the architecture, but with an increase 
in the diameter of the lobular units.
Duct ectasia: cystic dilation of the galactophore 
ducts. Microscopically, it is characterized by variable 
ductal dilation, surrounded by a dense fibrous stroma, 
frequently associated with mononuclear inflammatory 
infiltrate (Figure 3D). It can present proteinaceous and 
homogeneous secretion with the presence of foam cells.
Figure 3 –  (A): Glycogen rich carcinoma. Epithelial cells arranged in a predominantly solid pattern, 
tumor cells present an ample, granular, and foamy clear cytoplasm (arrow), and moderate 
cellular pleomorfism. H&E. 40x; (B); Fibroadenoma. Epithelial cells in a tubular array 
enveloped abundantly by fibroblast stromal elements. H&E. 2x; (C): Fibroepithelial 
hyperplasia. Proliferation of ducts lined by one or more layers of epithelial cells, surrounded 
by edematous and loose connective tissue. H&E. 4x; (D): Duct ectasia. Variable ductal 
dilation, surrounded by a dense fibrous stroma. H&E. 10x
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Histological grading
Like mammary carcinomas in bitches, histopathological 
grading of feline mammary tumors is of extreme importance 
(CAVALCANTI; CASSALI, 2006; MENDES et al., 2007; 
DUTRA et al., 2008; ESTRELA-LIMA et al., 2010). 
Histological grading is based on evaluations of tubular 
formation, nuclear pleomorphism and mitotic count 
(ELSTON; ELLIS, 1991). In veterinary medicine, there 
are some histological grading systems with specific criteria 
(GILBERTSON et al., 1983; LAGADIC; ESTRADA, 1990; 
ELSTON; ELLIS, 1991; MISDORP et al., 1999), and, due 
to the importance of histological grading as a prognostic 
factor and of the differences found between canine and 
feline mammary neoplasia, a species-specific system has 
been sought (MILLS et al., 2015). However, the method 
proposed by Elston and Ellis (1991; 1998) (Table 3) is the 
most widely used and has been described as an independent 
prognostic factor in malignant mammary neoplasia in cats 
(SEIXAS et al., 2011; CAMPOS et al., 2015). Therefore, 
the authors believe this method should be preferred until 
clear evidence of improved prognostic stratification is 
demonstrated with novel methods.
Table 3 – Nottingham system 
Characteristics Score
Tubular formation > 75% 1
10–75% 2
< 10% 3
Nuclear pleomorphism Mild 1
Moderate 2
Marked 3
Mitotic count* 0–8 1
9–16 2
> 17 3
Sum of scores Degree
3–5 I
6–7 II
8–9 III
*  Adapted according to the size of the field of microscopy used in this study = 
0.55 mm
Source: Elston, Ellis (1991, 1998)
Prognostic factors
Knowledge of the prognostic factors is extremely 
important in the determination of therapeutic programs 
for human breast cancer patients, with adequate and 
individualized intensity and effectiveness (ABREU; 
KOIFMAN, 2002). Prognostic factors are clinical, 
pathological and biological characteristics of the individuals 
and their tumors that allow predictions of clinical evolution 
and patient survival (ALLRED et al., 1998).
Tumor size is considered an important prognostic 
factor in cats, with tumors larger than 3 cm interfering 
negatively in overall survival (OS) and disease-free 
survival (MACEWEN et al., 1984; FOX et al., 1995; 
MACY, 1997; VISTE et al., 2002; OVERLEY et al., 2005; 
LANA et al., 2007; BORREGO et al., 2009). Other factors 
include the extent of surgery, type and histological grade, 
mitotic index, clinical staging, molecular markers and 
regional and distant metastases (NOVOSAD et al., 2006; 
LANA et al., 2007; GIMENÉZ et al., 2010; HUGHES; 
DOBSON, 2012).
Clinical staging considers the evaluation of the primary 
tumor, regional lymph nodes and possible distant metastasis 
sites (LANA et al., 2007). Although Borrego et al. (2009) 
did not demonstrate the prognostic value of clinical 
staging, with no difference between medians of disease-
free survival and OS, Novosad et al. (2006) demonstrated 
significantly longer disease-free survival for animals 
classified as stage I and the authors believe clinical stage 
assessment is important for therapeutic planning.
Seixas et al. (2011) reported higher OS associated with 
diagnoses of tubulopapillary and complex carcinomas 
compared with solid and micropapillary carcinomas. 
Novosad et al. (2006) reported lower OS in anaplastic 
carcinomas and higher OS in papillary and tubular 
carcinomas. Further studies with long-term follow-up are 
necessary to confirm the prognostic value of histologic type 
in feline mammary neoplasms.
Histological grade, evaluated by the Nottingham 
system, proposed by Elston and Ellis (1991), has been 
described as a reliable and independent prognostic 
factor in malignant mammary neoplasia in cats 
(SEIXAS et al., 2011; CAMPOS et al., 2015). The prognostic 
value was demonstrated by lower OS associated with 
more undifferentiated tumors (MILLANTA et al., 2002a; 
SEIXAS et al., 2011; CAMPOS et al., 2015).
The immunohistochemical evaluation of the cell 
proliferation index through immunostaining with Ki-67 
is an excellent marker to determine the growth fraction 
in a given cell population (MILLANTA et al., 2002a). 
Previous studies on mammary lesions in cats describe a 
progressive increase in proliferative index from normal 
mammary glands, non-neoplastic lesions, benign tumors, 
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in situ carcinomas, invasive carcinomas and metastases 
(MILLANTA et al., 2002a; DIAS PEREIRA et al., 
2004; CAMPOS et al., 2015). In a recent study, Soares 
et  al.  (2016a) demonstrated that the Ki-67 index can 
be used as a prognostic biomarker in feline mammary 
carcinomas, especially in those with values greater than 
14%, which correlate positively with low OS, larger tumor 
size, low differentiation, presence of necrosis and negative 
status for epidermal growth factor receptor 2 (ErbB-2; 
HER2 in humans) and oestrogen receptor (ER).
The role of ovarian hormones in feline mammary 
neoplasia was evidenced by Overley et al. (2005) and 
Hayden et al. (1989), who observed loss of protection 
against the disease with increased hormonal exposure, 
prevalence of intact cats with mammary tumors when 
compared with the spayed population and sporadic 
occurrence of mammary lesions concomitant with the 
use of progestins. Despite these findings, feline mammary 
tumors are considered models of hormone-independent 
breast cancer in women because most tumors are 
considered negative for ER and progesterone receptor (PR) 
(LAS MULAS et al., 2000, 2002; MILLANTA et al., 2005a; 
LANA et al., 2007). However, a recent study described 
the prevalence of positive tumors for ER and PR using 
the recommendations of the American Society of Clinical 
Oncology and the American College of Pathologists for 
hormone receptor positivity (CAMPOS  et  al., 2015). 
Millanta et al. (2006) found a similar result using a cut-off 
point for positivity to hormonal receptors above 5%. No 
association was found between ER and PR expression and 
OS in feline mammary neoplasia (MILLANTA et al., 2005).
Ordás et al. (2007) reported an association between 
tumors with ErbB-2 overexpression and characteristics that 
are indicative of increased malignancy: larger size, high 
histological grade and absence of hormone receptors. In 
addition, the prognostic significance of ErbB-2 expression 
was demonstrated by Millanta et al. (2005b) and Campos 
et al. (2015), with lower OS associated with higher 
ErbB-2 scores.
Cyclooxygenase 2 (Cox-2) is a rapidly induced 
enzyme involved in the malignant transformation 
process and tumor progression by interfering with cell 
proliferation and adhesion, apoptosis, immunological 
surveillance and angiogenesis (WILLIAMS et al., 1999; 
MILLANTA et al., 2006). The increase in Cox-2 expression 
was associated with lower OS, as described by Millanta et 
al. (2006) and Campos et al. (2015).
Classification of molecular subtypes
As in humans, mammary tumors in dogs and cats 
have gained new classifications according to molecular 
and prognostic studies (SOARES et al., 2016b, 2016c). 
Molecular phenotype has become important in the 
definition of tumor subtypes, based on the expression 
of immunohistochemical markers, such as ER and PR, 
ErbB-2 overexpression, CK expression (CK 5/6, CK 14 
and CK 17) and the epidermal growth factor receptor 
(EGFR) (HEROLD; ANDERS, 2013). In recent years, these 
markers have also been used in the molecular phenotyping 
of mammary neoplasia in cats, but with some differences 
in markers, evaluation methods and classification systems 
among the different study groups (BRUNETTI et al., 2013; 
WIESE et al., 2013; SOARES et al., 2016b, 2016c).
Wiese et al. classified 24 mammary tumors in cats 
based on the expression of ER, PR, ErbB-2, CK 5/6 and 
EGFR markers. The tumors were classified as luminal A 
(ER+, PR+/– and ErbB-2–) or luminal B (ER+, PR+/– 
and ErbB-2+) and those with ErbB-2 overexpression 
(ER–, PR+/– and ErbB-2+) or basal-like expression (CK 
5/6+ and/or EGFR+). In that study, 19 (79.2%) basal-
like tumors were identified; however, these data were 
not correlated with pathanatomical and clinical factors. 
In that same year, Brunetti et al. (2013) performed the 
molecular phenotyping of 21 feline mammary tumors, 
considering the expression profiles of the markers ER, 
PR, ErbB-2, CK 5/6, CK 14 and p63. The authors did 
not identify luminal A (ER+ and/or PR+, ErbB-2– and 
indifferent CK 5/6 or CK 14 or p63) or normal-like (all 
negative markers) tumors but did report 11 (52.4%) 
cases of subtype luminal B (ER+ and/or PR+, ErbB-2+ 
and CK 5/6 or CK 14 or p63 indifferent), eight (38.1%) 
cases of ErbB-2 overexpression (ER–, PR–, ErbB-2+ and 
indifferent CK 5/6 or CK 14 or p63) and two (9.5%) basal-
like cases (ER–, PR–, ErbB-2–, CK 5/6+ and/or CK 14+ 
and/or p63+). Likewise, the molecular subtypes were not 
correlated with the prognostic factors and clinical follow-
up of the animals, but the authors reported a discrepancy in 
the molecular phenotype between the primary tumor and 
its respective metastasis in 43% of the cases. Using the same 
panel and classification system, except for CK 14 and p63, 
Muscatello et al. (2015) evaluated five feline tumors via the 
tissue microarray (TMA) method. The authors reported 
three cases of subtype luminal B and two cases of ErbB-2 
overexpression but also did not correlate the findings with 
clinical and pathological data.
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In 2013, the St. Gallen International Expert Consensus 
panel proposed a different molecular classification for breast 
tumors in women, in which it established six biologically 
distinct subtypes of breast cancer: luminal A, luminal 
B/HER2-negative, luminal B/HER2-positive, HER2-
positive (non-luminal), basal-like triple-negative and 
normal-like triple-negative (GOLDHIRSCH et al., 2013). 
Ki-67 expression has also been used as a prognostic and 
predictive factor in the response to breast cancer treatment 
(LUPORSI et al., 2012). Recently, this classification was 
used in the clinicopathological evaluation of 266 mammary 
tumors in 102 cats, according to the criteria described in 
table 4 (SOARES et al., 2016b; 2016c).
Regarding the positivity criteria established by Soares 
et al. (2016a, 2016b, 2016c), mammary tumors in cats 
were considered positive for ER and/or PR when there 
was positive staining in more than 1% of the neoplastic 
cells, according to the Allred Score (positive when > 2). 
For ErbB-2, the tumor was considered positive when the 
neoplastic cells had +2 or +3 staining scores. A score of +2 
was characterized by complete staining of the membrane, 
even if it was weak or not uniform, but with an obvious 
circumferential distribution in at least 10% of cells; and 
a score of +3 was characterized by intense and uniform 
staining in at least 10% of the tumor cells. For CK 5/6 
and/or CK 14, the tumor was considered positive when 
there was cytoplasmic or membrane staining in at least 
1% of the neoplastic cells. Regarding Ki-67, after counting 
the positive cells in 1000 cells, the tumor was considered 
to have high proliferation when it showed a proliferative 
index greater than 14%.
In the study by Soares et al. (2016b), the most 
prevalent subtype was luminal B/ ErbB2-negative (29.4%), 
followed by luminal B/ ErbB2-positive (19.6%), triple-
negative (16.7%), luminal A (14.7%), normal-like triple-
negative (12.7%) and ErbB2-positive (6.9%). The authors 
demonstrated a positive correlation between the basal-like 
and normal-like triple-negative subtypes and larger tumor 
size and prevalence of necrotic areas, along with positive 
correlations between the luminal B/ErbB2-positive, basal-
like and normal-like triple-negative subtypes with less 
differentiated tumors. However, although the animals with 
the luminal A subtypes had longer OS and longer disease-
free time, unlike the animals with basal-like triple-negative 
subtypes, which exhibited the shortest times, there was no 
significant difference in this study.
Subsequently, Soares et al. (2016c) evaluated disease 
progression in 61 cats with metastasis. After multivariate 
analysis, it was determined that molecular classification is 
an independent prognostic factor for OS and that animals 
with ErbB-2-positive or basal-like triple-negative tumor 
subtypes have a higher chance of death relative to the other 
molecular subtypes. In addition, a high cell proliferation 
index (Ki-67 > 14%), tumor size and ulceration were also 
confirmed to be prognostic predictors of OS. Finally, the 
authors demonstrated increases in cell proliferation, ErbB-
2 overexpression and CK 5/6 appearance in the metastases 
linked to their primary tumors, suggesting that the disease 
progresses to more aggressive molecular subtypes.
Currently, evaluating the status of ER and PR is one 
of the pillars of mammary cancer diagnosis. Compared 
with humans, cats appear to exhibit different trends in this 
status, and a high percentage of feline mammary tumors 
are negative for ER. Therefore, these observations suggest 
that these tumors may be appropriate models for advanced 
stages of ER-negative breast cancer in women (MILLANTA 
et al., 2005; ZAPPULLI et al., 2005). The investigation of 
potential new markers provides information relevant for 
clinical management and the understanding of neoplastic 
molecular pathogenesis and may have implications for the 
use of feline mammary tumors as spontaneous models for 
human disease (HUGHES; DOBSON, 2012).
Table 4 –  Molecular classification of subtypes of feline mammary tumors
Luminal A
Luminal B
ErbB-2 positive
Triple-Negative
ErbB-2 - ErbB-2 + Basal-like Normal-like
ER + and/or PR+ + and/or PR+ + and/or PR+ - - -
PR + and/or ER+ + and/or ER+ + and/or ER+ - - -
ErbB-2 - - + + - -
CK 5/6 indifferent indifferent indifferent indifferent + -
Ki-67 < 14% > 14% ns ns ns ns
NS: not significant
Source: Soares et al. (2016b, 2016c)
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Treatment
Fibroepithelial hyperplasia
Treatment of fibroepithelial hyperplasia involves 
supportive care, including the use of analgesics, 
antibiotics, anti-inflammatories, diuretics, corticosteroids 
and warm compresses several times a day (OGILVIEG; 
MOORE, 2001). The PR antagonist, aglepristone, may 
be used at the dose of 10 mg/kg subcutaneously for 
four to five consecutive days (WEHREND et al., 2001) 
or 20 mg/kg once weekly (GORLINGER et al., 2002). 
Repeated treatments may be required for animals 
previously treated with exogenous progestogens for up to 
five weeks (JURKA; MAX, 2009). The definitive treatment 
consists of the removal of exogenous hormone exposure 
or oophorectomy (GIMENEZ et al., 2010). Fibroepithelial 
hyperplasia treatment should be performed only after 
the natural resolution of the disease, or with surgical 
access via the flank. As hyperplasia tends to decrease 
after hormonal stimulation, mastectomy is not indicated, 
solely reserved for cases of necrosis and extensive 
ulceration or when there is no response to clinical 
treatment (GIMENEZ et al., 2010). However, mammary 
involution may take from one to six months to fully occur 
(GORLINGER et al., 2002).
Surgery
Surgery is the main treatment recommended for feline 
mammary tumors (MISDORP, 2002) and can be performed 
in combination with other types of therapies, such as 
chemotherapy (LANA et al., 2007). Unilateral or bilateral 
radical mastectomy, regardless of tumor size and lesion 
location, is the surgical technique of choice and has been 
associated with a reduction of tumor recurrences, although 
it does not promote an increase in OS (MACEWEN et al., 
1984; LANA et al., 2007; MCNEILL et al., 2009), which is 
the recommendation of the authors of the present paper. 
A previous study described significant OS differences 
associated with different surgical procedures, with higher 
OS in cats submitted to bilateral radical mastectomies 
(NOVOSAD et al., 2006).
Sentinel lymph node
The regional, axillary and inguinal, lymph nodes, 
even if not clinically altered, should be excised at the 
time of mastectomy due to the high incidence of regional 
metastases (CUNHA et al., 2016). For the axillary lymph 
node lymphadenectomy (Figure 4), Patent Blue dye (2.5%) 
is applied intradermally at a dose of 2 mg/kg, without 
exceeding the volume of 1 ml per patient, to facilitate the 
identification and removal of the lymphatic tissue.
Figure 4 –  Female cat patient placed in dorsal decubitus position for mastectomy. 
(A): Patent Blue intradermal application; (B): Twenty minutes after the 
intradermal application of the Patent Blue dye in 4 points distributed 
around the first mammary gland. Skin incision and divulsion of the 
subcutaneous and pectoral muscles in the middle third of the axillary 
region; (C): Identification of the axillary lymph node stained by patent 
blue; (D): Axillary lymph node of the patient after lymphadenectomy
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Chemotherapy
Several clinical, histopathological and 
immunohistochemical parameters can be evaluated to 
determine the need for antineoplastic chemotherapy 
treatment. As discussed during the 3rd Mammary 
Pathology Meeting, current literature findings and the 
authors` experience indicate that adjuvant chemotherapy 
should be proposed for patients with malignant tumors 
larger than three centimetres in diameter, evidence of 
metastasis in regional or distant lymph nodes, and, after 
histopathological evaluation, invasion of neoplastic cells 
in lymphatic or blood vessels, histological grade III, and 
aggressive histological types, such as micropapillary 
carcinoma, solid carcinoma, cribriform carcinoma and 
carcinosarcoma. During the immunohistochemical 
examination, if the Ki-67 is greater than 14%, the use of 
antineoplastic chemotherapy in the postoperative period 
is also indicated. Further studies should be performed to 
reevaluate the indications for chemotherapy as described.
However, the response to chemotherapy in animals 
diagnosed with metastases may not be satisfactory 
(GIMENÉZ et al., 2010). The chemotherapy protocols 
proposed by the literature consist of the use of doxorubicin 
as the only drug or in combination with cyclophosphamide, 
carboplatin as the only drug or in combination with 
doxorubicin and mitoxantrone as the only drug or in 
combination with cyclophosphamide (KITCHELL et al., 
1999; LANA et al., 2007; CAMPOS et al., 2014; CUNHA et 
al., 2015). Additional clinical studies should be conducted to 
assess which doses and chemotherapeutic combinations are 
most effective in increasing the OS (GIMENÉZ et al., 2010).
Previous studies have evaluated the use of doxorubicin 
as adjuvant chemotherapy in malignant feline mammary 
neoplasia (NOVOSAD et al., 2006; MCNEILL et al., 2009) 
and the association of this chemotherapy drug with Cox-
2 inhibitors (BORREGO et al., 2009). Novosad et al. 
(2006) observed an increase in survival when surgery was 
associated with doxorubicin (median of 641 days after five 
cycles of chemotherapy), but the study did not include 
a control population. Borrego et al. (2009) also found 
a high median OS (460 days) when treating cats with 
malignant mammary neoplasia with surgery, doxorubicin 
and a non-selective Cox-2 inhibitor (meloxicam) at a 
dose of 0.2 mg/kg/SC/SID, on the day of the surgical 
procedure, followed by 0.1 mg/kg/VO/SID for five days, 
followed by 0.025 mg/kg/VO/SID during antineoplastic 
chemotherapy treatment); however, this study did not 
include a control population. McNeill et al. (2009) did 
not observe a beneficial effect of the combination of 
chemotherapy with doxorubicin and surgery (median 
848 days) when compared with cats treated with surgery 
alone (median 1,406 days). In addition, doxorubicin 
may be nephrotoxic in cats, therefore requiring careful 
evaluation of renal function (LANA et al., 2007). Another 
drug that can be used as a non-selective Cox-2 inhibitor 
is piroxicam at a dose of 0.3 mg/kg every 48 hours 
(BULMAN-FLEMING et al., 2010).
Carboplatin was proposed as a rescue therapy agent 
as either a single drug or in combination with other 
antineoplastic drugs (mitoxantrone and doxorubicin) for 
malignant feline mammary neoplasia with recurrence 
or metastases (NOVOSAD et al., 2006). Campos et al. 
(2014) did not observe a significant difference between 
cats diagnosed with malignant neoplasia of the mammary 
gland treated with surgery alone (median OS of 387 
days) and treated with surgery and chemotherapy with 
carboplatin (median of OS of 428 days). However, the OSs 
described in that study were greater than the OS described 
in the literature (less than one year), demonstrating the 
efficiency of the surgical treatment. Literature findings 
regarding feline mammary neoplasms remain scarce and 
are generally composed of a small number of studied 
patients and, therefore, more research is needed.
Follow-up
After diagnosis of a malignant mammary tumor, it is 
essential to schedule routine re-evaluations of the feline 
patient for early disease detection. This reassessment 
includes haematological examinations (complete blood 
count and serum biochemical profile) to evaluate the 
patient’s general condition and possible paraneoplastic 
syndromes, along with imaging tests (abdominal 
ultrasonography and thoracic radiographs) to assess 
evidence of asymptomatic metastases. The protocol 
indicated by the group is to perform re-evaluations every 
two months in the first six months after diagnosis and every 
three months between six and 24 months.
Final considerations
Feline mammary tumors present a challenge to the 
veterinarian clinician due to their guarded to poor prognosis. 
Thus, it is necessary to define new therapeutic approaches 
and to obtain more in-depth knowledge of the disease in 
this species. The available literature on feline mammary 
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tumors can still be considered scarce. In addition, most of 
the studies found in the literature evaluate a small number 
of animals and are usually performed retrospectively and 
with methodologies that may be considered questionable. 
Therefore, even manuscripts with positive results may have 
an arguable validity. Papers that mainly evaluate pathological 
characteristics of mammary neoplasia in cats also usually 
present serious failures in methodology standardization. 
Therefore, different studies addressing the same topic cannot 
be added together since results vary greatly depending on 
the methodology employed. Furthermore, there is likely a 
reduced demand for veterinary care in veterinary reference 
centers by cat guardians. However, the reduced sample 
numbers of animals in each study can be circumvented with 
the collaboration of several institutions, thus generating 
larger multicentre studies. Several authors consider feline 
mammary tumors a model for the study of human neoplasia 
due to the similarities of several clinical and pathological 
features. We can then assume that the reverse path is also 
possible. Many methodologies in human medicine are well 
established after studies that demonstrate their effectiveness. 
The possibility of methodological standardization in 
veterinary medicine would allow a significant increase in 
the knowledge of the diseases that affect our patients.
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